Diagnosed prevalent cases of Parkinson’s disease to reach 3.15 million in 7MM by 2033: GlobalData Read more
Parkinson’s disease clinical research in 7MM focuses on disease-modifying agents: GlobalData Read more
Zydus gains final USFDA approval for Amantadine extended-release capsules 68.5 mg and tentative approval for 137 mg Read more
Zydus receives USFDA approval to initiate Phase II clinical trial of ZYIL1 for Parkinson’s disease Read more
SPARC completes enrolment in PROSEEK, Phase 2 study of Vodobatinib in early Parkinson’s disease Read more
Amneal Parkinson’s drug IPX203 needs to compete with novel subcutaneous levodopa delivery systems post FDA CRL: GlobalData Read more
Urgent need for disease-modifying drugs to arrest Parkinson’s disease progression: GlobalData Read more